[1]张伯礼.面向未来:世界需要中医药[J].医学争鸣,2016,(01):1-4.[doi:10.13276/j.issn.1674-8913.2016.01.001]
 ZHANG Bo-Li.For the future: the world needs Traditional Chinese Medicine[J].,2016,(01):1-4.[doi:10.13276/j.issn.1674-8913.2016.01.001]
点击复制

面向未来:世界需要中医药

参考文献/References:

[1] 张伯礼. 主编新年寄语[J]. 中医杂志, 2013, 54(1):1.
[2] 张伯礼. 系统生物学将推动中药复杂体系的深入研究[J].中国天然药物, 2009, 7(4):241.
[3] Wang C, Cao B, Liu QQ, et al. Oseltamivir compared withthe Chinese traditional therapy maxingshigan-yinqiaosanin the treatment of H1N1 influenza: a randomized trial[J].Ann Intern Med, 2011, 155(4):217-225.
[4] Li X, Zhang J, Huang J, et al. A multicenter, randomized,double-blind, parallel-group, placebo-controlled study ofthe effects of qili qiangxin capsules in patients with chronicheart failure[J]. J Am Coll Cardiol, 2013, 62(12):1065-1072.
[5] Shang H, Zhang J, Yao C, et al. Qi-shen-yi-qi drippingpills for the secondary prevention of myocardial infarction:a randomised clinical trial[J]. Evid Based ComplementAlternat Med, 2013, 2013:738391.
[6] Phase II multi-center study of T89 to treat chronic stableangina (T89 phase 2)[EB/OL].(2012-12-10) [2015-06].https://www.clinicaltrials.gov/ct2/show/NCT00797953?term=tasly&rank=6.
[7] Phase III trial of Dantonic® (T89) Capsule to prevent and treatstable angina (CAESA) [EB/OL]. (2015-05-19) [2015-06].https://www.clinicaltrials.gov/ct2/show/NCT01659580?term=tasly&rank=3.
[8] Assess the antifibrotic activity of Fuzheng Huayu in chronichepatitis C patients with hepatic fibrosis[EB/OL]. (2014-06-18)[2015-06]. https://www.clinicaltrials.gov/ct2/show/study/NCT00854087?cond=hepatic+fibrosis&spons=shanghai&rank=3.
[9] Efficacy and safety study of lipid-lowering effects ofXueZhiKang (XZK) in patients with hyperlipidemia[EB/OL].(2014-07-22) [2015-06]. https://clinicaltrials.gov/ct2/show/NCT01327014?term=xuezhikang&rank=3.
[10] Gruenwald J. The global herbs & botanicals market[EB/OL].[2015-06]. https://www.otciq.com/otciq/ajax/show FinancialReportById.pdf?id=27951.
[11] 张伯礼. 主编新年寄语[J]. 中医杂志, 2015, 56(1):1.

相似文献/References:

[1]彭恩胜,陈江勇.影响中医药文化核心价值体系建设的若干维度[J].医学争鸣,2014,(03):28.
 PENG En-Sheng,CHEN Jiang-Yong.Multiple dimensional analysis about the construction of TCM culture core-value system[J].,2014,(01):28.
[2]唐汉庆.中医药转化医学研究实验室建设面临的问题及对策[J].医学争鸣,2014,(03):32.
 TANG Han-Qing.Problems and solutions of constructing laboratory of translational Chinese medicine[J].,2014,(01):32.
[3]张金哲.儿科人文医学的应用尤具意义[J].医学争鸣,2015,(05):1.[doi:10.13276/j.issn.1674-8913.2015.05.001]
[4]吴秋芳.深化医改必须走出“唯临床”怪圈[J].医学争鸣,2015,(05):12.[doi:10.13276/j.issn.1674-8913.2015.05.004]
 WU Qiu-Fang.Deepening medical reform must be free from the eccentricview that only clinic comes first[J].,2015,(01):12.[doi:10.13276/j.issn.1674-8913.2015.05.004]
[5]毕礼明,陈英兰,奉典旭.转化医学与中医防治肾脏病研究策略[J].医学争鸣,2016,(05):38.[doi:10.13276/j.issn.1674-8913.2016.05.011]
 BI Li-Ming,CHEN Ying-Lan,FENG Dian-Xu.Translational medicine and research strategies of renaldisease prevention and therapy with Chinese medicine[J].,2016,(01):38.[doi:10.13276/j.issn.1674-8913.2016.05.011]
[6]蔡燕峰,金小晶.中药+质子泵抑制剂:根除幽门螺杆菌治疗 的新方案探讨[J].医学争鸣,2017,(04):62.[doi:10.13276/j.issn.1674-8913.2017.04.017]
 CAI Yan-Feng,JIN Xiao-Jing.Chinese medicine plus proton pump inhibitor: a new Helicobacter pylori eradication scheme[J].,2017,(01):62.[doi:10.13276/j.issn.1674-8913.2017.04.017]
[7]周小玲,章新友,仵倚,等.“互联网+”中医药的SWOT分析与对策[J].医学争鸣,2017,(05):45.[doi:10.13276/j.issn.1674-8913.2017.05.013]
 ZHOU Xiao-Ling,ZHANG Xin-You,WU Yi,et al.SWOT analysis and countermeasures of “Internet plus” traditional Chinese medicine[J].,2017,(01):45.[doi:10.13276/j.issn.1674-8913.2017.05.013]
[8]陈 哲,李惠林,李增英,等.“miRNA—肾主骨—骨质疏松”相关性假说[J].医学争鸣,2018,(06):28.[doi:10.13276/j.issn.1674-8913.2018.06.008]
 CHEN Zhe,LI Huilin,LI Zengying,et al.A correlation hypothesis of “miRNA-kidney dominating bones-osteoporosis”[J].,2018,(01):28.[doi:10.13276/j.issn.1674-8913.2018.06.008]
[9]谢子妍,由凤鸣,金 钊,等.口腔微生物移位定植——中医药干预结肠炎癌转化新窗口[J].医学争鸣,2018,(06):48.[doi:10.13276/j.issn.1674-8913.2018.06.014]
 XIE Ziyan,YOU Fengming,JIN Zhao,et al.Oral microorganism transplantation/colonization —New consideration of traditional Chinese medicine intervention in IBD-CRC[J].,2018,(01):48.[doi:10.13276/j.issn.1674-8913.2018.06.014]
[10]王诗源,菅广峰,陈莉军,等.中医药健康旅游产业发展存在的问题及对策[J].医学争鸣,2019,(01):15.[doi:10.13276/j.issn.1674-8913.2019.01.005]
 WANG Shiyuan,JIAN Guangfeng,CHEN Lijun,et al.Problems and countermeasures in the development of traditional Chinese medicine health tourism industry[J].,2019,(01):15.[doi:10.13276/j.issn.1674-8913.2019.01.005]

备注/Memo

作者简介:张伯礼。中医药学专家,中国工程院院士,天津中医药大学校长,中国中医科学院院长。中华中医药学会副会长,中华预防医学会副会长,中国中西医结合学会名誉会长。国家重大新药创制重大专项技术副总师,国务院医改咨询专家委员会成员。Tel:022-59596123 Email:zhangbolipr@163.com

更新日期/Last Update: 2016-01-20